Published 6 issues per year
ISSN Print: 0743-4863
ISSN Online: 2162-660X
Indexed in
Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs
ABSTRACT
Pulmonary tuberculosis (TB) is a leading cause of death worldwide and is caused by the pathogen Mycobacterium tuberculosis (MTb). As treatment for TB, dry powders for inhalation (DPIs) are considered stable compared with nebulizers and metered dose inhalers and are suitable for high-dose formulations. Although extensive research has been done over the last two to three decades on nanocarrier-based DPIs for targeting MTb infection, none of the anti-TB DPI formulations have reached the market. Challenges in the proper assessment of nanocarrier-based DPIs due to the complexity of lungs is one of the reasons. In this review, the details of in vitro evaluation parameters of nanocarriers and nanocarrier-based DPIs along with their need and basic principles are discussed. Further, the thorough in vitro, ex vivo, and in vivo pharmacological evaluations, together with their procedures wherever required, are covered. The different evaluation parameters during process development, release specifications, and stability studies suggested by U.S. Food and Drug Administration Center for Drug Evaluation and Research to apply for new drug applications and abbreviated new drug applications of DPIs are also discussed. Lastly, the evaluation parameters for DPIs provided in European, United States, British, and Indian pharmacopeias are summarized.
-
Patil Tulshidas S., Deshpande Ashwini S., Design, development, and characterisation of clofazimine-loaded mannosylated nanostructured lipid carriers: 33-Box-Behnken design approach, Materials Technology, 36, 8, 2021. Crossref
-
Dholakia Jheel, Prabhakar Bala, Shende Pravin, Strategies for the delivery of antidiabetic drugs via intranasal route, International Journal of Pharmaceutics, 608, 2021. Crossref
-
Patil Tulshidas S., Deshpande Ashwini S., Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine, Drug Development and Industrial Pharmacy, 47, 3, 2021. Crossref
-
Rath Goutam, Pradhan Deepak, Ghosh Goutam, Goyal Amit K., Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis, Current Pharmaceutical Design, 27, 17, 2021. Crossref
-
Ogienko Andrey G., Myz Svetlana A., Nefedov Andrey A., Ogienko Anna A., Adamova Tatyana P., Voronkova Olga M., Amosova Svetlana V., Trofimov Boris A., Boldyrev Vladimir V., Boldyreva Elena V., Clathrate Hydrates of Organic Solvents as Auxiliary Intermediates in Pharmaceutical Research and Development: Improving Dissolution Behaviour of a New Anti-Tuberculosis Drug, Perchlozon, Pharmaceutics, 14, 3, 2022. Crossref
-
Sheikh Bashir A., Bhat Basharat A., Alshehri Bader, Mir Rakeeb A., Mir Wajahat R., Parry Zahoor A., Mir Manzoor A., Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis, Journal of Biomedical Nanotechnology, 17, 12, 2021. Crossref
-
Belgamwar Veena, Bhoyar Vidyadevi, Trivedi Sagar, Patel Miral, Nanoparticles for the targeted drug delivery in lung cancer, in Photophysics and Nanophysics in Therapeutics, 2022. Crossref
-
Fan Zi, Zhou Bo, Liu Yujia, Sun Wu, Fang Yuntao, Lu Hongguo, Chen Dongya, Lu Kuikui, Wu Xinyue, Xiao Tian, Xie Wenjing, Bian Qian, Optimization and Application of an Efficient and Stable Inhalation Exposure System for Rodents, AAPS PharmSciTech, 23, 1, 2022. Crossref